Migraine is a common neurological disorder that afflicts up to 15% of the adult 
population in most countries, with predominance in females. It is characterized 
by episodic, often disabling headache, photophobia and phonophobia, autonomic 
symptoms (nausea and vomiting), and in a subgroup an aura in the beginning of 
the attack. Although still debated, many researchers consider migraine to be a 
disorder in which CNS dysfunction plays a pivotal role while various parts of 
the trigeminal system are necessary for the expression of associated 
symptoms.Treatment of migraine has in recent years seen the development of drugs 
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide 
(CGRP) or its receptor. Several of these drugs are now approved for use in 
frequent episodic and in chronic migraine. CGRP-related therapies offer 
considerable improvements over existing drugs, as they are the first to be 
designed specifically to act on the trigeminal pain system: they are more 
specific and have little or no adverse effects. Small molecule CGRP receptor 
antagonists, gepants, are effective for acute relief of migraine headache, 
whereas monoclonal antibodies against CGRP (Eptinezumab, Fremanezumab, and 
Galcanezumab) or the CGRP receptor (Erenumab) effectively prevent migraine 
attacks. The neurobiology of CGRP signaling is briefly summarized together with 
key clinical evidence for the role of CGRP in migraine headache, including the 
efficacy of CGRP-targeted treatments.